Ahmedabad based drug major Cadila Pharmaceuticals Limited (CPL) in collabration with US based Novavax is likely to become the first Indian company to launch the vaccine for swine flu HIN1 virus in the country by the end of this year. If the government puts the processing of the project on the fast track and gives necessary permission for clinical trials, the vaccine can be made available to the public by December. At the Serum Institute of India in Pune, a crack team of 16 scientists is running a battle against time as part of the global race to develop vaccines against the spread of swine flu. Scientists at the institute say the first vaccines will be ready by September. But it will be at least six months before the vaccine will be ready for mass use. Two other Indian companies - the New Delhi-based Panacea Biotec and the Hyderabad-based Bharat Biotech - have also joined the race for the vaccine. Sam Panthaky Novartis leads the race and Swiss drugmaker Novartis has begun injecting the swine flu vaccine it has developed into human volunteers, in the company's first human trials. The vaccine is being tested in a year long trial on 6,000 people of all ages in Britain, Germany and the United States. More than 35 countries have already placed orders with Novartis for the swine flu or H1N1 vaccine. India has already made it clear that it will import the vaccine from any country that makes it first.